INTRODUCTION
============

Nandrolone is included in the class II of anabolic androgenic steroids (AAS) which is composed of *19-nor-testosterone-derivates*. In general, AAS is a broad and rapidly increasing group of synthetic androgens used both clinically and illicitly. Nandrolone is applicable in clinical practice, burns, radiation therapy, surgery, trauma and various forms of anemia \[[@R1]\]. Moreover, it has also been used to treat chronic debilitating diseases: human immuno-deficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-associated wasting syndrome \[[@R2]\]. However, due to its beneficial properties such as tissue-building booster, maintenance of strength and muscle mass, libido and bone health it has become very popular among athletes in their attempt to increase their strength, to accelerate muscle development, to promote recovery and enhance aggression \[[@R3]\]. The compound is famous not only among adults but also adolescents because of its anabolic, muscle building properties \[[@R4]-[@R7]\]. It is considered worldwide to be one of the most commonly abused AAS \[[@R8],[@R9]\]. Despite the previously mentioned desired effects there are also many harmful effects on the central nervous system (CNS) which have been stated in literature.

Structurally, nandrolone and compounds belonging to the class II of AAS, differ from testosterone at the C19 position where a methyl group (CH~3~) is substituted by a hydrogen. The previously mentioned substitution leads to the half-time extension beyond that contributed by esterification alone. Esterification of the hydroxy group (OH) at the C17 position of nandrolone with decanoic acid yields ND \[[@R10]\]. It is worth saying that despite the retention of the C4--C5 double bond in ND, the androgenic activity of the compound is reduced at the androgen receptor compared to dihydrotestosterone and is more anabolic than testosterone \[[@R10]-[@R12]\].

The chemical structures of nandrolone decanoate, testosterone and 5β-dihydrotestosterone are reported in Fig. **[1](#F1){ref-type="fig"}**.

Despite the fact that AAS are banned substances by professional sport organizations and illegal drugs by the DEA, they are used and abused extensively, especially by teenagers and young athletes or non-athletes either for cosmetic or recreational purposes. Users may even take from 10 to 100 times higher doses than the physiological one \[[@R7]\].

MATERIALS AND METHODS
=====================

The following databases (from 1980 to January 2014) Medline, Cochrane Central, Scopus, Web of Science and Science Direct were used, searching the following key words: Nandrolone decanoate (ND), Anabolic androgenic steroids (AAS), neurological effects, behavior, anxiety, aggression, learning, memory, reproductive behaviors, locomotion, reward and endocrine system. The first two key words, ND and AAS, were searched singularly and associated individually to each of the other keywords. Among the 3084 sources found, 113 were considered as appropriate for the purpose of the paper.

RESULTS
=======

Aggression
----------

There is a correlation between administration of nandrolone decanoate (ND) and aggressive behavior, in fact increased aggressive behavior \[[@R13]\] has been shown in many studies but contradictory outcomes when using different methodological approaches no effect on aggression \[[@R14]-[@R18]\] have been reported as well.

*Breuer et al.*\[[@R14]\] investigated the effects on Long-Evans rats after being treated with ND, testosterone propionate or stanozolol (5 mg/kg 5 times/week for 12 weeks) concluding that aggressive behavior had increased in rats treated with testosterone propionate compared to controls. In contrast, ND administered rats and control groups demonstrated similar aggressive levels.

*Findings of Breuer et al*\[[@R14]\] are consistent with *Albert et al.*\[[@R19]\] who showed that both ND treated rats and controls exposed few lateral attacks when undergoing a competitive test situation.

*McGinnis et al*\[[@R16]\] carried out tests to find whether AAS - enhanced aggression is reversible. They assessed aggression in male rats following withdrawal from ND, stanozolol, ortestosterone propionate; 5 mg/kg 5 days a week for 12 weeks. Rats receiving ND showed similar aggressive behavior to controls. On the other hand, *Long et al*. \[[@R13]\] stated that Sprague--Dawley rats treated with ND (2 mg/day or 20 mg/week for 4 weeks) showed increased levels of aggression compared to controls. Discrepancies between the findings of *Long et al*. and later studies \[[@R14],[@R15]\] could not be fully explained, but may be attributed to differences in rat strain (Long- Evans versus Sprague--Dawley) and/or particular testing conditions.

Studies carried out subsequently failed to find aggression in either adult or adolescent male rats after ND administration \[[@R20],[@R21]\]. However, the results from *Long et al*. may be attributed to experience since the nadrolone-treated males used for this specific study were given two weeks of fight training prior to the initiation of ND administration. Males in the other studies had no former aggressive experience.

Rats in *McGinnis et al*. \[[@R15]\]. The fact that the effect (no effect) of ND on intermale aggression was replicated \[[@R14], [@R15]\] demonstrates that under particular testing conditions ND does not promote aggression in Long-Evans male rats.

*Lindqvis et al*. \[[@R22]\] administered rats with ND ((15 mg/kg) for 14 days) to examine competitive aggression. Starting from one week after the ultimate ND injection, the Wistar rats were acclimated in new cages and with new cage-mates for 3 days. On the fourth day, water intake was restricted and competitive aggressive behaviors demonstrated by AAS and vehicle-treated rats were recorded upon introduction of an active waterspout. Baseline levels of water intake were determined after the test when rats were placed in individual cages. Baseline levels of drinking were similar among the groups. However, during the test AAS-treated rats spent more time drinking. Therefore it is difficult to interpret these findings since the test was carried out a week after the last ND administration and the clearance rate of ND is unknown.

Series of experiments have been conducted by*Melloni and colleagues*\[[@R23]-[@R25]\] on gonadally intact adolescent male hamsters after their treatment with a cocktail of ND, testosterone cypionate and boldenone undecylenate. Hamsters treated for 14 days with AAS demonstrated more attacks and bites and a reduced latency to bite the intruder compared to controls. Similar results observed in subsequent studies by the same lab on hamsters treated with the AAS coctail for 30 days \[[@R26]-[@R28]\].

Male Syrian hamsters were treated daily with a combination containing ND, testosterone cypionate and boldenone undecylenate (2, 2, 1mg/kg, respectively) either during adolescence or adulthood for 14 days. The day after the treatment ended, males were tested for either sexual behavior or agonistic behavior with a receptive female or a male intruder, respectively. Adult AAS -- treated males displayed lower levels of sexual behavior and no heightened aggression compared to controls whereas, the corresponding adolescent males showed significant increase in aggressive and sexual behavior compared to controls \[[@R29]\].

For experimental purposes rats were stimulated by a mild tail pinch by the experimenter. Reactivity to such stimuli was tested using ND-treated animals and controls after the cessation of the ND treatment period and up to six to eight weeks afterwards. It has been shown that animals displayed enhanced reactivity concerning air puffs, flank prods and capturing, on both test occasions. *McGinnis et al.*exported the same results as both studies enhanced reactivity a few weeks after the end of the noted nandrolone-treatment. *McGinnis et al*tested the behavioral responses to tail pinches 12 weeks after the cessation of the steroid treatment and observed no enhanced aggressive behaviors.

*Rossbach et al*. \[[@R30]\] demonstrated that AAS can increase excitatory neurotransmission in adult rodents *via*augmented phosphorylation of the NMDA receptor glutamate which results in an increment of aggression, impulsiveness and irritability in adult and adolescent rats.

Interaction between ND and NMDA sites as well as sigma receptors has been considered. For the purposes of the study, male rats were daily administered ND for 14 days. Presuming that ND might react on the brain through interaction with neurosteroids. Radiolabelled \[3H\]ifenprodil was employed in the binding experiments as it shows a significant affinity for both NMDA and sigma receptors. It was reported that \[3H\]ifenprodil binds to both sigma-1 and sigma-2 sites and can be displaced to some extent from both sites by the neurosteroids dehydroepiandrosterone sulphate (DHEAS), pregnenolone sulphate (PS), and pregnanolone sulphate (3a5bS). The remaining \[3H\]ifenprodil was displaced from the site of sigma-1 by the (þ)-SKF 10,047, which is a sigma-1 receptor-selective ligand. Chronic treatment with nandrolone altered the sigma-1 receptor affinity with the above mentioned neurosteroids but sigma--2 receptor remained unchangeable. Moreover it was noted that NMDA receptor subunit NR2B was not affected by treatment with ND.

Arginin Vasopressin (AV) has been implicated in inducing aggressive behavior. *Harrison et al*. \[[@R28]\] have demonstrated that treatment of preadolescent male hamsters with a cocktail including ND for a 30 days period resulted in increased aggression compared to controls. It was also noticed that the average area innervated by AV immuno-reactive fibers in the anterior hypothalamus and AV content were increased.

The region most affected in the expression of aggressive behavior is the hypothalamus. N-methyl-D-aspartate receptor (NMDA) involved in the inductance of some types of aggressive response \[[@R31]\]. The NMDA receptor subunit mRNA expression levels are significantly decreased after 14 days of treatment with AAS \[[@R32]\].

According to *Tamaki T. et al*\[[@R33]\] elevated levels of adrenergic and serotonergic amines, nandrolone-stimulated, in the hypothalamus could bring about an improved physical performance but also aggressive behavior.

The androgen action is related to its ability to bind and activate specific androgen receptors. The immunoreactivity of substance P (SP), which is a peptidergic factor associated with enhanced aggression in several brain regions, amygdala, hypothalamus, periaqueductal gray area and striatum, \[[@R34]\] has been shown to increase after ND administration. ND has also been shown to react on the SP system at several levels, including receptor densities, peptide concentrations and enzymatic processing \[[@R35],[@R36]\]. Chronic treatment with ND has been associated with impact on both opioid concentrations and the tachykinin levels in brain areas connected with the control of emotional behavior such as depression, aggression and reward.

Enhanced c-fos expression has been noted in limbic brain regions involving the behavioral, stress and reward systems, in the guinea pig after being treated with ND \[[@R37]\]. Hypothalamic vasopressin levels increased and offensive aggression has been facilitated in adolescent male Syrian hamsters after repeated treatment with AAS \[[@R26]\].

According to *Carrillo et al*and*Fisher et al*\[[@R38], [@R39]\] exposure to nandrolone during adolescence alters the normal activity of the glutamatergic system in the latero anterior hypothalamus (LAH), brain regions involved in the expression of aggressive behavior. Other studies \[[@R40]-[@R42]\] showed that nandrolone induces aggression in mice only at high anabolic doses through experiments conducted on the gastrocnemius muscle which is hormone-sensitive.

Anxiety, Fear and Stress
------------------------

Anxiogenic \[[@R43]\] and anxiolytic effects \[[@R44]\] have been associated with nandrolone. *Kouvelas D. et al*\[[@R45]\] suggest that chronic treatment with high doses of ND induces anxiolytic-type behavior, an impaired social memory, possible spatial learning and recall performance *via*activation of the central androgenic receptors (ARs), while the acquisition of information remains unaltered. In rats administered with ND (15 mg/kg subcutaneously) and flutamide (FL), an AR antagonist, reduction of anxiety was abolished. Contrarily, in a former study when FL was applied to the hippocampus, an increased anxiety-like behavior was noted, possibly as a result of interaction between the drug and targets other than ARs \[[@R46]\]. Interaction of ND and FL with the ARs in brain areas, is known to contribute to anxiety-related behavior such as hypothalamus, basal ganglia, amygdala, septum, hippocampus, motor nuclei in the brain stem, cerebellum, spinal cord, andcerebral cortex, by interfering with serotonergic, glutamatergic, dopaminergic pathways, which may lead to anxiety reduction and memory impairment.

On the other hand, *Minkin et al*. \[[@R43]\] noticed that Long-Evans rats (gonadally intact or gonadectomized) following ND treatment (10 or 50 mg/week for 8 weeks) spent more time compared to controls in the margins of the open-field (i.e. thigmotaxis), suggesting an increased level of anxiety. Same results were reported by *Minkin and Meyer*since anxiogenic response was induced in rats treated with ND during the open field task.

Nandrolone enhances synaptic currents mediated by the GABAA receptor in the ventromedial nucleus of the hypothalamus, but diminishes them in the pre-optic area \[[@R47]\]. These effects depend on the subunit composition of the GABAA receptor. In the dorsomedial hypothalamus, blockade and enhancement of GABAA-mediated currents are associated to anxiogenic responses \[[@R48]\] and anxiolysis \[[@R49]\], respectively.

Reward and Dependence
---------------------

Psychostimulants, such as cocaine and d-amphetamine, elevate extracellular dopamine (DA) concentrations by the reuptake inhibition of the DA transporters \[[@R50]\]. Up-regulation of the DA transporters in the caudatum/putamen has been noticed after treatment with ND \[[@R51], [@R52]\] suggesting to reflect a response of an enhanced DA activity \[[@R53]\]. The effects of d-amphetamine (0.5 mg/kg 15 min prior to test) on brain stimulation reward were studied before and after the rats were administered with a cocktail containing ND, testosterone cypionate and boldenone undecylenate (2, 2, 1 mg/ kg daily for 15 weeks) \[[@R54]\]. It was suggested that although ND has no direct effect on the brain reward system, it potentiates the rewarding effects of amphetamine.

*Santa Kailanto et al*. \[[@R55]\] suggest that prolonged changes in rats' brain reward circuits associated to drug dependence could be produced after ND treatment (20 mg/kg intramuscularly (i.m.) every other day over a 10-day period). The high concentrations of extracellular DA and serotonin (5-HT), evoked by the cocaine were attenuated by pretreatment with ND. Changes noticed in DA and 5-HT systems after ND treatment, were still persistent after a significantly long period after the cessation of the administration.

*Kurling S. et al*. suggest that pretreatment with ND could modulate the rewarding effects evoked by MDMA and amphetamines. \[[@R50], [@R56]\]. Taking into account that activation of the dopaminergic neuronal system in mesolimbic brain areas, is believed to play a crucial role in mediating the reward-related effects of drugs of abuse the results provided here are in accordance with studies reporting that ND has the ability to decrease morphine reward \[[@R57]\] and alter some of the effects of cannabinoids when used chronically \[[@R58]\]. Moreover, its chronic administration could blunt the subjective effects of cocaine in rats

*Kurling-Kailanto S. et al*\[[@R59]\] suggest that AASs can produce some alterations in brain reward systems that contribute to the maintaining of drug dependence. Realistically, ND showed an important action at the doses tested, on the satisfying effects of cocaine. It was indicated that subchronic pretreatment with ND weakens dose-dependently the reward-related behavioral and neuro-chemical results of acute cocaine use. Both behavioral and neurochemical effects of ND were apparent for at least 28 days after the cessation of the treatment.

Few possible mechanisms have been suggested explaining how ND can react on dopaminergic response to cocaine. Activation of monoamine oxidase (MAO) could lead to elevation of the metabolism of both DA and 5-HT. However, the latter is not supported by the outcomes of *Thiblin et al*. \[[@R60]\] since MAO activity was not changed by ND. Pretreatment with ND also weakened the cocaine-induced increase of extracellular 5-HT in the nucleus accumbens (NAc) dose-dependency.

In summing up, we can say that ND dose-dependency inhibits both the DA and 5-HT outflow in NAc which is caused by cocaine and decreases cocaine-induced behavioral effects in experimental animals. Taking into account that total outflow of both DA and 5-HT is considered to be related to the pleasing stimulant drugs-induced effects, it suggests that ND may modulate the delectable effects of cocaine.

Animal studies showed that AAS can promote dependency and a link between the effects of AAS and opioids has been reported \[[@R61]\]. It is difficult to distinguish between the direct and the indirect AAS rewards which result in an increased strength in humans. It has been showed in animal studies that AAS reward and athletic performance are irrelevant. Chronic treatment with ND in rats heightened the levels of endogenous opioids and their receptors in select limbic regions, including elevation in beta-endorphin in the ventral tegmental area (VTA) \[[@R62]\]. However, we must remember that, dissimilar with many drugs of abuse, AASs do not acutely stimulate the dopamine release in the NAc \[[@R63]\].

Learning, Memory and Work Capacity
----------------------------------

According to*Magnusson K. et al*\[[@R64]\] nandrolone administered male rats displayed memory function impairment, possibly *via*dynorphinergic mechanisms in the hippocampus. The hippocampus is a brain region associated with cognitive function since the limbic brain is linked to several types of learning and memory functions. This region displays a relatively high density of androgen receptors in rats, which suggests a relationship between the androgen receptor and cognitive function \[[@R65]-[@R69]\].

Locomotion and Physical Activity
--------------------------------

*McGinnisM Y et al*\[[@R70]\] studied the wheel running activity and circadian rhythmicity in gonadal intact male rats after treatment with three different AAS (stanozolol, testosterone and nadrolone). Rats exposed to nandrolone showed a significant decrease when running on the wheel whereas none of the AASs altered phase response and circadian rhythmicity measures.

Nandrolone effect on locomotor activity is controversial. Some studies found that nandrolone had no effect on locomotion \[[@R71]\] whereas other findings suggest that nandrolone phenylpropionate-treated rats displayed increased running endurance compared to controls \[[@R72]\].

Impact of ND on the Endocrine System: Effects on the HPAA (Hypothalamic---Pituitary--- Adrenal Axis)
----------------------------------------------------------------------------------------------------

The effect of ND on HPAA has been shown in some studies. Effects on the corticosterone, adrenocorticotropin hormone, proopiomelanocortin, corticotropin releasing factor (CRF) and CRF receptor1 (CRF R1) mRNA in the pituitary, hypothalamus and amygdala of rats have been noted. Moreover effects of ND on adiponectin, insulin, ghrelin, leptin and corticosterone (CORT), and cortical serotoninergic system (CSS) have been observed \[[@R73]-[@R75]\].

Racca S. *et al*. \[[@R73]\] evaluated the effects of subchronic administration of ND (once a day for 14 days) on HPAA and CSS response to acute restraint stress (RS). Acute RS produced the following effects: increase in adrenocorticotrophin (ACTH) (both in blood and in pituitary corticotropes) and CORT (in blood), glucocorticoid receptor (GR) reduction in the hippocampus and hypothalamus cytosol and GR translocation in hippocampus nuclear fraction, stimulation of the cortical serotonin re-uptake and activation of hippocampus cytosolic ERK2. ND itself, i.e. in non-stressed rats, had no effect on these parameters, apart from a raise in hippocampus cytosolic phospho-ERK1/2 (hippocampal extracellular signal related kinase) and a decrease of plasma CORT and ACTH levels. In contrast, in stressed ND-treated rats stress-induced plasma ACTH increase and all other above mentioned stress effects were prevented, apart from an increment in pituitary ACTH positive cell density. Although, prolonged supratherapeutical doses of ND administration in rats, did not notably affect HPAA and serotonin transporter activity under no-stress conditions, they may deregulate the stress-induced hormonal cascade which plays a crucial role in depressive psychopathology.

Considerable reduction in CORT plasma levels in rats after ND treatment (15 mg/kg for 14 days) has been noted by *Alsio et al*\[[@R74]\]. Decreased expression of two key enzymes involved in CORT synthesis (5a-reductase I and 11b-OHase) in adrenals of rats identified after prolonged ND treatment, suggesting that chronic treatment with ND could impair CORT adrenal release by acting on the gene transcription of enzymes involved in CORT synthesis.

Moreover, nandrolone treatment increased HMGCR (steroid synthesising enzymes in adrenal gland) expression in the adrenals and reduced expression levels of the b3-adrenoceptor in the adipose tissue. Indeed, nandrolone may reduce adiponectin *via*a direct effect on the adipocyte, as indicated by cell culture experiments \[[@R76]\].

It is worth saying that the expression of adiponectin is affected by plasma CORT and that the reduced levels of adiponectin in the present study may result from the simultaneous reduction in CORT \[[@R77]\]. Cardiovascular and metabolic unhealthiness correlated with ND abuse is mediated by reduced adiponectin levels \[[@R78]-[@R80]\], since adiponectin has both anti-atherogenic and anti-diabetic effects \[[@R81]\]. Moreover cardiovascular disease has been associated with reduced circulating levels of adiponectin \[[@R82]\].

*Schlussman et al*. \[[@R75]\] suggested, after experiments with ND treated rats (either 45 mg/kg for 14 days or 15 mg/kg ND for 3 days), that ND action on stress response is dose and/or time dependent. A decrease in circulating CORT levels 24 h after the cessation of long term -- treatment (14 days) and a considerable increase in circulating CORT levels 1 h after the end of short term-- treatment (3 days) and a return to the control levels 24h later was noted. Differences in time course of ND effects were observed in mRNA levels of various components of the HPA. No alterations in mRNA levels of hypothalamic CRF, anterior pituitary proopiomelanocortin (POMC) or anterior pituitary CRF R1 were observed. However, a considerable decrease in both anterior pituitary POMC and hypothalamic CRF have been reported in a chronic study with ND.

Nandrolone and Neurotransmitters: γ-Aminobutyric Acid Type A (GABAA) Receptors
------------------------------------------------------------------------------

Studies have demonstrated that chronic treatment with ND changes GABAergic transmission in neural circuits that play a crucial role in the expression of aggression. ND enhances synaptic currents mediated by the GABAA receptor in the ventromedial nucleus of the hypothalamus, but diminishes them in the pre-optic area \[[@R83]\].

Specifically, there was a semantically increased release of neurons from the central amygdala (CeA) projecting to the nucleus bed of the stria terminalis (BnST) and to the GABAA receptor-mediated inhibition which target BnST neurons. \[[@R84]\] GABAergic transmission in the mammalian forebrain has been associated to aggression \[[@R85]\], reproductive behavior, stress \[[@R88]\] and anxiety expression.

Effect of the AAS on ion channels in the CNS has been observed both in social isolation \[[@R89]\] and chronic AAS exposure \[[@R90]\]. Increased expression of the α5 subunit of the GABAA receptor in forebrain regions associated with aggression and anxiety development \[[@R91]\] (including hippocampus, amyglada, \[[@R92]\] medial pre optic area \[[@R93], [@R94]\], and the frontal cortex) \[[@R95]\] has been noted.

Although AASs have been shown to alter GABAA receptor expression after chronic treatment \[[@R94]\], when given acutely they allosterically modulate the GABAA receptor function \[[@R96]\].

The GABAA receptor subunit gene expression is regulated by both 17b-estradiol \[[@R97]\] and testosterone \[[@R98]\], possibly by signaling receptors mediated by nuclear androgen and estrogen. AAS may mimic these gonadal steroids by acting on these receptors \[[@R99]\].

According to studies, AASs alter the synthesis of endogenous neurosteroids and of GABA synthesizing enzymes. Such alteration in endogenous neurosteroid levels may affect the brain and all behaviors associated with AAS abuse.

5-Hydroxytryptamine (5-HT) and 5-HT Receptors
---------------------------------------------

The serotonergic, 5-HT, pathways originate in the midbrain, the raphe nuclei and innervate the ventral tegmental area, \[[@R100]\] the substantia nigra, \[[@R83]\] the nucleus accumbens and the striatum \[[@R101]\]. Serotonergic activity regulates sexual behavior, aggression, fear, anxiety and reward \[[@R102]\].

Attenuation of the 5-HT system has been involved with increased aggression in humans and animals \[[@R103], [@R104]\].

According to*Kurling S et al*\[[@R105]\] supraphysiological doses of ND (20 mg/kg) considerably increased the concentrations of 5-HT in the hippocampus, hippocampus and cerebral cortex.

*Thiblin et al.*\[[@R60]\] evaluated the effects of different AASs including among others ND and testosterone propionate on Sprague--Dawley rats. They found that 5-HT metabolism (measured as a ratio of 5-HT to 5-hydroxyindoleacetic acid) was enhanced in the hippocampus, but 5-HT synthesis rate was not significantly increased. Conflicting results presented in earlier studies suggested that treatment with testosterone propionate resulted in decreased levels of 5-HT in the diencephalon \[[@R106]\] and in the hippocampus \[[@R107]\].

*Racca S et al*\[[@R73]\] evaluated the effect of ND on HPAA and cortical serotoninergic system activity in response to acute restrain (RS). In non-stressed ND treated animals no effect on 5-HT re-uptake was observed while it entirely impaired the raise of serotonin transporter (SERT) activity caused by acute RS, probably as a consequence of the stress-induced increase of 5-HT levels in the synaptic cleft.

Dopamine and Dopamine Receptors
-------------------------------

Young Syrian hamsters treated with AAS produced increased levels of dopamine (DA) and dopamine D2 receptor (DA D2R) expression in the anterior hypothalamus \[[@R108], [@R109]\]. DA D2Rs are androgen sensitive and AAS treatment considerably increases D2 mRNA expression in the brain \[[@R110]\]. Increased D2R immune-reactivity in the hypothalamus (AH) has been noticed after treatment with AAS in young hamsters by *Ricci et al*. \[[@R111]\]. As the activation of D2Rs enhance neuronal inhibition, a rise in DA and D2R expression in the AH indicates that hypothalamic DA enhances aggression. Another theory implicates disinhibitory mechanism for enhanced expression of aggressiveness. In this way, a blockade of D2Rs would allow an increased GABAergic inhibition on the excitatory AH neurons. It is assumed that these D2-GABAergic neurons synapse on vasopressin (VP) neurons within the AH. In addition, GABA was previously considered to be able to modulate VP activity in the AH \[[@R112]\]. Hypothalamic VP activity has been proved to play a crucial role in aggression control.

Opioids and Opioid Receptors
----------------------------

Alterations in the endogenous opioid system, because of AAS administration, were first reported in 1995 \[[@R92]\]. Dynorphin B (Dyn B) and met-enkephalin-Arg6Phe7 (MEAP) are opioids, which serve as markers for two genetically different opioid peptide system activities.

ND affects both enkephalin and dynorphin systems in striatum, AH and periaqueductal gray (PAG). Moreover, chronic administration induces an imbalance in nucleus accumbens (structures associated with reward mechanisms) \[[@R113]\].

CONCLUSIONS
===========

ND is able to cause several psychological effects, a graphical representation is reported in Fig. **[2](#F2){ref-type="fig"}**. Many of the effects and the associated mechanisms have been explained in detail in the present review.

To sum up, serotonin, glutamate and dopamine systems, activation of GABAA and NMDA receptors as well as activation of steroid receptors such as estrogen, mineralocorticoid, progesterone and glucocorticoid receptors could all contribute to the altered behaviors described.
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